Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: A posthoc pooled analysis of seven randomized controlled studies

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1381-1392

  Gopal, Srihari ^a   Liu, Yanning ^a   Alphs, Larry ^b   Savitz, Adam ^a   Nuamah, Isaac ^a   Hough, David ^a  

^a LLC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic agents; Extrapyramidal symptoms; Long acting injectable; Movement disorder; Second generation

Indexed keywords

BENZATROPINE; BIPERIDEN; DIPHENHYDRAMINE; HYDROXYZINE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; TRIHEXYPHENIDYL;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AKATHISIA; ARTICLE; BARNES AKATHISIA SCALE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERKINESIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONSET AGE; PARKINSONISM; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIMPSON ANGUS RATING SCALE; TREMOR;

EID: 84884372046     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S49944     Document Type: Article

References (33)

1. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14:152-164.
2. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol. 1998;13 Suppl 3:S49-S57.
3. Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry. 2000;2:194-204.
4. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61 Suppl 3:16-21.
5. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13:13-24.
6. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm. 1989;8:691-709.
7. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70:627-643.
8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
9. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59:69-75.
10. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191-208.
11. Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64:216-239.
12. McCrea M, Pliskin N, Barth J, et al. Official position of the military TBI task force on the role of neuropsychology and rehabilitation psychology in the evaluation, management, and research of military veterans with traumatic brain injury. Clin Neuropsychol. 2008;22:10-26.
13. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;17:194-201.
14. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93:117-130.
15. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25:247-256.
16. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90:147-161.
17. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13:635-647.
18. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62:1363-1370.
19. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35: 2072-2082.
20. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235-244.
21. Pope A, Adams C, Paton C, Weaver T, Barnes TR. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry. 2010;197:67-72.
22. Guy W. Abnormal Involuntary Movement Scale. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept of Health Education and Welfare; 1976.
23. Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. Adv Psychiatr Treat. 2000;6:332-341.
24. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
25. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
26. Gopal S, Berwaerts J, Nuamah I, et al. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat. 2011;7: 93-101.
27. Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:181-188.
28. Kasten M, Bruggemann N, Konig IR, et al. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl). 2011;214:729-736.
29. Lencer R, Eismann G, Kasten M, et al. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry. 2004;185:465-471.
30. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15:111-117.
31. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28:210-213.
32. Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs. 2007;67:1541-1566.
33. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24:287-296.